![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
-Diketo Acids and Resistance of the Soluble Double-Mutant (F185K/C280S)
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (C.M., A.A.J., K.C., T.A.P., Y.P.); and Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute, Frederick, Maryland (R.G.K., G.C.G.P., X.Z., M.C.N., T.R.B.)
The 
-diketo acids (DKAs) represent a major advance for anti–HIV-1 integrase drug development. We compared the inhibition of HIV-1 integrase by six DKA derivatives using the wild-type enzyme or the double-mutant F185K/C280S, which has been previously used for crystal structure determinations. With the wild-type enzyme, we found that DKAs could be classified into two groups: those similarly potent in the presence of magnesium and manganese and those potent in manganese and relatively ineffective in the presence of magnesium. Both the aromatic and the carboxylic or tetrazole functions of DKAs determined their metal selectivity. The F185K/C280S enzyme was markedly more active in the presence of manganese than magnesium. The F185K/C280S integrase was also relatively resistant to the same group of DKAs that were potent in the presence of magnesium with the wild-type enzyme. Resistance was caused by a synergistic effect from both the F185K and C280S mutations. Molecular modeling and docking suggested metal-dependent differences for binding of DKAs. Molecular modeling also indicated that the tetrazole or the azido groups of some derivatives could directly chelate magnesium or manganese in the integrase catalytic site. Together, these experiments suggest that DKAs recognize conformational differences between wild-type and the double-mutant HIV-1 integrase, because they chelate the magnesium or manganese in the enzyme active site and compete for DNA binding.
Address correspondence to: Dr. Yves Pommier, Laboratory of Molecular Pharmacology, Center for Cancer Research, Bldg. 37, Rm. 5068, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255. E-mail: pommier{at}nih.gov
This article has been cited by other articles:
|
|
 |
|
  C. N. Alves, S. Marti, R. Castillo, J. Andres, V. Moliner, I. Tunon, and E. Silla A Quantum Mechanic/Molecular Mechanic Study of the Wild-Type and N155S Mutant HIV-1 Integrase Complexed with Diketo Acid Biophys. J., April 1, 2008; 94(7): 2443 - 2451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Pandey, S. Bera, J. Zahm, A. Vora, K. Stillmock, D. Hazuda, and D. P. Grandgenett Inhibition of Human Immunodeficiency Virus Type 1 Concerted Integration by Strand Transfer Inhibitors Which Recognize a Transient Structural Intermediate J. Virol., November 15, 2007; 81(22): 12189 - 12199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nunthaboot, S. Pianwanit, V. Parasuk, J. O. Ebalunode, J. M. Briggs, and S. Kokpol Hybrid Quantum Mechanical/Molecular Mechanical Molecular Dynamics Simulations of HIV-1 Integrase/Inhibitor Complexes Biophys. J., November 15, 2007; 93(10): 3613 - 3626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Johnson, C. Marchand, S. S. Patil, R. Costi, R. Di Santo, T. R. Burke Jr., and Y. Pommier Probing HIV-1 Integrase Inhibitor Binding Sites with Position-Specific Integrase-DNA Cross-Linking Assays Mol. Pharmacol., March 1, 2007; 71(3): 893 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Marchand, K. Krajewski, H.-F. Lee, S. Antony, A. A. Johnson, R. Amin, P. Roller, M. Kvaratskhelia, and Y. Pommier Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites Nucleic Acids Res., October 6, 2006; (2006) gkl667v3. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Agapkina, M. Smolov, S. Barbe, E. Zubin, T. Zatsepin, E. Deprez, M. Le Bret, J.-F. Mouscadet, and M. Gottikh Probing of HIV-1 Integrase/DNA Interactions Using Novel Analogs of Viral DNA J. Biol. Chem., April 28, 2006; 281(17): 11530 - 11540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Semenova, A. A. Johnson, C. Marchand, D. A. Davis, R. Yarchoan, and Y. Pommier Preferential Inhibition of the Magnesium-Dependent Strand Transfer Reaction of HIV-1 Integrase by {alpha}-Hydroxytropolones Mol. Pharmacol., April 1, 2006; 69(4): 1454 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Johnson, W. Santos, G. C. G. Pais, C. Marchand, R. Amin, T. R. Burke Jr., G. Verdine, and Y. Pommier Integration Requires a Specific Interaction of the Donor DNA Terminal 5'-Cytosine with Glutamine 148 of the HIV-1 Integrase Flexible Loop J. Biol. Chem., January 6, 2006; 281(1): 461 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, H. Klock, H. Yin, K. Wolff, K. Bieza, K. Niswonger, J. Matzen, D. Gunderson, J. Hale, S. Lesley, et al. Homogeneous High-Throughput Screening Assays for HIV-1 Integrase 3{beta}-Processing and Strand Transfer Activities J Biomol Screen, August 1, 2005; 10(5): 456 - 462. [Abstract] [PDF]
|
|
|
|
|
|
S. Bonnenfant, C. M. Thomas, C. Vita, F. Subra, E. Deprez, F. Zouhiri, D. Desmaele, J. d'Angelo, J. F. Mouscadet, and H. Leh Styrylquinolines, Integrase Inhibitors Acting Prior to Integration: a New Mechanism of Action for Anti-Integrase Agents J. Virol., June 1, 2004; 78(11): 5728 - 5736. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
